Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

77.01 +0.50 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,453,659
Open 76.03
Bid (Size) 76.37 (1)
Ask (Size) 77.00 (2)
Prev. Close 76.51
Today's Range 75.74 - 78.29
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 3.90%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing prices, it dropped 4.7% in 2 sessions. 
Via Benzinga

Performance

YTD
-7.48%
-7.48%
1 Month
+11.88%
+11.88%
3 Month
+16.79%
+16.79%
6 Month
-2.61%
-2.61%
1 Year
+0.20%
+0.20%

More News

Read More
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
This Is What Whales Are Betting On Gilead Sciences
Via Benzinga
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Via Benzinga
Check Out What Whales Are Doing With GILD
Via Benzinga
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Via The Motley Fool
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Via Benzinga
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
Via Talk Markets
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Via The Motley Fool
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Is Iovance Biotherapeutics a Millionaire Maker?
Via The Motley Fool
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.